<DOC>
	<DOCNO>NCT00426946</DOCNO>
	<brief_summary>The aim present study prospectively assess anti-depressant effectiveness reboxetine child adolescent , compare fluoxetine , randomize control open-label trial .</brief_summary>
	<brief_title>Reboxetine Treatment Depressed Children Adolescents 8-Week , Open Study</brief_title>
	<detailed_description>Introduction : Depression prevalent disorder involve 3 % child 8 % adolescent ( Birmaher et al , 1996 ) . Reboxetine , highly selective norepinephrine reuptake inhibitor , representative fairly new class antidepressant agent specificity noradrenergic system ( Kasper et al. , 2000 ) . Long-term clinical trial reboxetine treatment demonstrate reboxetine significantly effective placebo treatment major depression adult ( Versiani et al. , 1999 ) elderly ( &gt; 65 year ) ( Rampello et al. , 2005 ) patient . These long-term study demonstrate rebxetine well tolerate . Its adverse event mild severity require modification study medication ( Rampello et al. , 2005 ; Versiani et al. , 1999 ) . Few report publish use reboxetine child adolescent attention deficit/hyperactivity disorder ( ADHD ) ( e.g. , Mozes et al. , 2005 ) . In previous study ( Ratner et al. , 2005 ) , assess effectiveness reboxetine 6-week , prospective , open-label study . Thirty-one child adolescent ADHD treat reboxetine ( 4 mg/day ) , significant decrease ADHD symptom scale measure . To best knowledge , study publish use reboxetine treatment depress child . Fluoxetine drug choice treatment depression child adolescent . Fluoxetine find effective well tolerate several study , include double blind control one ( e.g. , March et al. , 2004 ) . The aim present study prospectively assess anti-depressant effectiveness reboxetine child adolescent , compare fluoxetine , randomize control open-label trial . Methods : 1 . The study randomize control open-label one . 2 . Sixty child adolescents 6-18 year old participate . 3 . Inclusion criterion : 1 . A diagnosis major depressive disorder dysthimic disorder accord DSM-IV-TR . 2 . Drug naïve without chronic medication least one month . 3 . Only child agree participate whose parent sign inform consent form include . 4 . Exclusion criterion : 1 . A diagnosis psychotic disorder bipolar disorder . 2 . Mental retardation . 3 . Alcohol drug abuse 4 . Chronic medical condition 5 . Girls ( &gt; 12 year ) include study possibility pregnancy study exist . 5 . All child undergo baseline psychiatric assessment child adolescent psychiatrist . In addition , participant undergo physical examination include weight , height , pulse rate blood pressure , electrocardiogram , blood assessment ( blood count , liver kidney function ) . 6 . After baseline assessment , participant include one two possible arm : 1. . An open randomize trial reboxetine ( 4 mg per day ) vs. fluoxetine ( 20 mg per day ) 4 week . A second psychiatric assessment support continuation dosage increase 8 mg reboxetine 40 mg fluoxetine . All child follow monitored side effect along entire study period . If clinical improvement occurs- dosage gradually decrease . If clinical improvement occur , child continue treatment accord clinical judgment . 2. . Children whose low-medium level depression lack suicidality point clinical decision psychotherapy treatment without drug therapy undergo baseline assessment assess 4 week psychotherapy . If decrease depressive symptom note less 40 % ( CDRS questionnaire ) less 2 ( CGI-I ) , reboxetine treatment initiate ( 8 week , open label ) . 7 . Rating Scales : 1 . Efficacy scale : I . Clinical Global Impression Scale Depression ( CGI-S ) ( Guy , 1976 ) II . Clinical Global Impression Improvement ( CGI-I ( Guy , 1976 ) III . Children ’ Depression Inventory CDI ( Kovacs , 1985 ) IV . Children ’ Depression Rating Scale-Revised ( CDRS-R ) ( Poznanski et al , 1979 ; Poznanski Mokros 1996 ) . V. Suicide Ideation Questionnaire-Short Version ( Reynolds , 1987 ) VI . Children 's Manifest Anxiety Scale ( RCMAS ) ( Reynolds Richmond , 1985 ; 1997 ) . VII . DSM-IV ADHD Scale ( DAS ) ) Spivak et al . 1999 ) 2 . Measuring autonomic arousal assess GSR- galvanic skin response ; heart rate variability EMG . Procompt , Thought Technology Company ; Biograph c , Assessment side effect : I . Weight height II . Pulse rate blood pressure III . Electrocardiogram IV . Spontaneous self report side effect assessment insomnia , somnolence , headache , gastrointestinal complaint , dizziness , agitation suicidality . Adverse effect ECG עוררות פיזיולוגית RCMAS SIQ-SV CDRS-R CDI CGI-I CGI-S - ּ+ + + + + + + T0 - + + + + + T2 - + + + + + + T4 - + T6 - + + + + + + T8 - + + + + + + + T12 T0- Baseline ; T2- 2 week reboxetine ; T4- 4 week reboxetine ; T6- 6 week reboxetine ; T8- 8 week reboxetine ; T12- 4 week end study period .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Reboxetine</mesh_term>
	<criteria>A diagnosis major depressive disorder dysthimic disorder accord DSMIVTR . Drug naïve without chronic medication least one month . Only child agree participate whose parent sign inform consent form include . A diagnosis psychotic disorder bipolar disorder . Mental retardation . Alcohol drug abuse Chronic medical condition Girls ( &gt; 12 year ) include study possibility pregnancy study exists .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>Depression Children Reboxetine</keyword>
	<keyword>A diagnosis major depressive disorder dysthimic disorder accord DSM-IV-TR .</keyword>
	<keyword>Drug naïve without chronic medication least one month .</keyword>
	<keyword>Only child agree participate whose parent sign inform consent form include .</keyword>
</DOC>